MA71713A - Acide usnique, ou leurs complexes d'inclusion, destinés à être utilisés dans le traitement d'infections à coronavirus ou provoquées par une bactérie - Google Patents
Acide usnique, ou leurs complexes d'inclusion, destinés à être utilisés dans le traitement d'infections à coronavirus ou provoquées par une bactérieInfo
- Publication number
- MA71713A MA71713A MA71713A MA71713A MA71713A MA 71713 A MA71713 A MA 71713A MA 71713 A MA71713 A MA 71713A MA 71713 A MA71713 A MA 71713A MA 71713 A MA71713 A MA 71713A
- Authority
- MA
- Morocco
- Prior art keywords
- coronavirus
- treatment
- bacterial infections
- inclusion complexes
- usnic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT202000032909 | 2020-12-30 | ||
| EP21847779.2A EP4271372A1 (fr) | 2020-12-30 | 2021-12-30 | Acide usnique, ou leurs complexes d'inclusion, destinés à être utilisés dans le traitement d'infections à coronavirus ou provoquées par une bactérie |
| PCT/IB2021/062486 WO2022144835A1 (fr) | 2020-12-30 | 2021-12-30 | Acide usnique, ou leurs complexes d'inclusion, destinés à être utilisés dans le traitement d'infections à coronavirus ou provoquées par une bactérie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71713A true MA71713A (fr) | 2025-05-30 |
Family
ID=75111772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71713A MA71713A (fr) | 2020-12-30 | 2021-12-30 | Acide usnique, ou leurs complexes d'inclusion, destinés à être utilisés dans le traitement d'infections à coronavirus ou provoquées par une bactérie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240058297A1 (fr) |
| EP (1) | EP4271372A1 (fr) |
| JP (1) | JP2024504031A (fr) |
| KR (1) | KR20230128069A (fr) |
| CN (1) | CN117120047A (fr) |
| AU (1) | AU2021412388A1 (fr) |
| CA (1) | CA3206672A1 (fr) |
| IL (1) | IL304012A (fr) |
| MA (1) | MA71713A (fr) |
| MX (1) | MX2023007941A (fr) |
| WO (1) | WO2022144835A1 (fr) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204901B (it) * | 1986-06-25 | 1989-03-10 | Iscofar Sas | Composizioni contenenti acido usnico o suoi derivati atte all'impiego nel trattamento della carie dentaria |
| JPH05246822A (ja) * | 1992-03-07 | 1993-09-24 | Nippon Paint Co Ltd | 抗菌剤 |
| CN104398477B (zh) * | 2014-10-30 | 2017-10-20 | 北京中医药大学 | 一种松萝酸纳米混悬液及其制备方法和用途 |
| FR3057773B1 (fr) * | 2016-10-21 | 2020-06-19 | Universite Claude Bernard Lyon 1 | Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus |
| EP3505154B1 (fr) * | 2017-12-26 | 2022-04-06 | Industrial Technology Research Institute | Composition pour améliorer la solubilité de substances faiblement solubles, son utilisation et formulation complexe la contenant |
| CN108635592B (zh) * | 2018-05-16 | 2021-06-22 | 重庆理工大学 | 一种松萝酸-磺丁基-β-环糊精超分子复合物及其在制备口腔护理产品中的应用 |
| US10463590B1 (en) * | 2018-12-20 | 2019-11-05 | Matthias W. Rath | Antiplaque and dental health oral formulation |
| IT201900021852A1 (it) * | 2019-11-21 | 2021-05-21 | Vestatis Gmbh | Composizione di estratti naturali avente attività antibatterica o batteriostatica anche per batteri Gram-negativi |
| CN111265528A (zh) * | 2020-01-21 | 2020-06-12 | 中国人民解放军军事科学院军事医学研究院 | 法匹拉韦在治疗冠状病毒感染方面的应用 |
| IT202000005515A1 (it) * | 2020-03-16 | 2021-09-16 | U Earth Biotech Ltd | Maschera filtrante perfezionata |
| US11419847B2 (en) * | 2020-04-10 | 2022-08-23 | Matthias W. Rath | Pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants |
| CA3189158A1 (fr) * | 2020-08-14 | 2022-02-17 | Anna Goc | Combinaison de micronutriments pour inhiber l'infection des cellules par un coronavirus |
| CN116392503A (zh) * | 2020-08-17 | 2023-07-07 | 中国海洋大学 | 海洋生物来源天然硫酸多糖在作为抗冠状病毒及所致疾病药物中的应用 |
| WO2023180567A1 (fr) * | 2022-03-24 | 2023-09-28 | Fundacion Privada Institut De Recerca De La Sida-Caixa | Cyclodextrines destinées à être utilisées dans une thérapie contre une infection à coronavirus |
-
2021
- 2021-12-30 CA CA3206672A patent/CA3206672A1/fr active Pending
- 2021-12-30 JP JP2023540112A patent/JP2024504031A/ja active Pending
- 2021-12-30 EP EP21847779.2A patent/EP4271372A1/fr active Pending
- 2021-12-30 US US18/269,738 patent/US20240058297A1/en active Pending
- 2021-12-30 WO PCT/IB2021/062486 patent/WO2022144835A1/fr not_active Ceased
- 2021-12-30 AU AU2021412388A patent/AU2021412388A1/en active Pending
- 2021-12-30 CN CN202180091657.1A patent/CN117120047A/zh active Pending
- 2021-12-30 MA MA71713A patent/MA71713A/fr unknown
- 2021-12-30 MX MX2023007941A patent/MX2023007941A/es unknown
- 2021-12-30 IL IL304012A patent/IL304012A/en unknown
- 2021-12-30 KR KR1020237025835A patent/KR20230128069A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240058297A1 (en) | 2024-02-22 |
| WO2022144835A1 (fr) | 2022-07-07 |
| CN117120047A (zh) | 2023-11-24 |
| IL304012A (en) | 2023-08-01 |
| AU2021412388A9 (en) | 2024-05-23 |
| KR20230128069A (ko) | 2023-09-01 |
| AU2021412388A1 (en) | 2023-07-13 |
| JP2024504031A (ja) | 2024-01-30 |
| CA3206672A1 (fr) | 2022-07-07 |
| MX2023007941A (es) | 2023-07-14 |
| EP4271372A1 (fr) | 2023-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4143207A4 (fr) | Composition vaccinale pour la prévention ou le traitement d'une infection par sras-cov-2 | |
| MA55796A (fr) | Dérivés d'acide itaconique et leurs utilisations dans le traitement d'une maladie inflammatoire ou d'une maladie associée à une réponse immunitaire indésirable | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA34002B1 (fr) | Thérapie antivirale | |
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA33716B1 (fr) | Mutants de fgf21 et leurs utilisations | |
| MA37317A1 (fr) | Formulation d'anticorps il-17 | |
| MA52154B1 (fr) | Composition pharmaceutique pour l'anémie | |
| EP4149481A4 (fr) | Thiosaccharides destinés à être utilisés dans le traitement d'une infection à coronavirus | |
| EP4228697A4 (fr) | Compositions pour la prévention ou le traitement d'infections virales et d'autres infections microbiennes | |
| EP4154881A4 (fr) | Applications d'un inhibiteur de kinase hpk1 dans la prévention et/ou le traitement d'une infection par un agent zoopathogène | |
| EP4121022A4 (fr) | Compositions et méthodes pour le traitement et la prévention d'une infection à coronavirus | |
| EP4301132A4 (fr) | Inhibiteur de rock2 pour le traitement d'une infection virale | |
| MA71713A (fr) | Acide usnique, ou leurs complexes d'inclusion, destinés à être utilisés dans le traitement d'infections à coronavirus ou provoquées par une bactérie | |
| MA47082B1 (fr) | Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1 | |
| BE1029585B1 (fr) | Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire | |
| EP3768274A4 (fr) | Composition destinée à être utilisée dans le traitement d'états provoqués par une déficience en calcium | |
| EP3909576A4 (fr) | Utilisation d'acide chlorogénique dans la préparation d'un médicament ou d'une composition pharmaceutique pour la prévention ou le traitement de la douleur | |
| EP3813816C0 (fr) | Utilisation de l'acide (s)-3-amino-4-(difluorométhylényl)cyclopent-1-ène-1-carboxylique et de composés apparentés, de l'acide (1s,3s)-3-amino-4-(difluorométhylidène)cyclopentane-1-carboxylique dans le traitement de le syndrome de l'x fragile ou le syndrome de tremblement/ataxie associé à l'x fragile | |
| FR3100128B1 (fr) | Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications | |
| EP4210727A4 (fr) | Compositions et leurs méthodes d'utilisation pour la prévention et le traitement d'infections grippales | |
| MA53706A (fr) | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne | |
| EP4203943A4 (fr) | Composés 1,2,4-trioxane et compositions les comprenant destinés à être utilisés pour la prévention et le traitement du cancer | |
| EP4098261A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement d'une stéatohépatite non alcoolique | |
| EP4106874A4 (fr) | Compositions et leurs méthodes d'utilisation pour le traitement d'une maladie neurodégénérative et mitochondriale |